Trending...
- Customized Stations Available for Jeron Pro-Alert™ Area of Rescue System
- Mayor Brandon Johnson Launches Public Application To Join Chicago's Reparations Task Force
- 99% of lab professionals impacted by medical couriers, survey finds
CHENGDU, China, April 24, 2025 ~ Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK) has announced that it will be showcasing the results of six clinical studies at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from May 30 to June 3. These studies, led by Kelun, include data from their TROP2 antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT), anti-PD-L1 mAb tagitanlimab, and RET inhibitor KL590586 (A400/EP0031).
The abstracts for these studies will be published on ASCO's official website on May 22, 2025, local time. The selected studies for ASCO 2025 are focused on various types of cancer and aim to present promising treatment options for patients.
One of the studies, titled "Sacituzumab tirumotecan (sac-TMT) in patients with previously treated advanced EGFR-mutated non-small cell lung cancer (NSCLC): Results from the randomized OptiTROP-Lung03 study," will be presented as an oral presentation on June 1st. This study focuses on the use of sac-TMT as a potential treatment option for patients with advanced NSCLC.
More on illi News
Another study, titled "Tagitanlimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (R/M NPC): Results from a randomized, double-blind, phase 3 study," will also be presented as an oral presentation on May 31st. This study looks at the effectiveness of tagitanlimab in combination with other treatments for patients with recurrent or metastatic nasopharyngeal carcinoma.
The Phase II OptiTROP-Breast05 study will also be presented as a rapid oral presentation on May 30th. This study focuses on the use of sac-TMT as a first-line treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/m TNBC).
In addition to these presentations, there will also be a poster presentation on May 31st for the study titled "Sacituzumab tirumotecan (sac-TMT) in combination with tagitanlimab (anti-PD-L1) in first-line (1L) advanced non-small-cell lung cancer (NSCLC): Non-squamous cohort from the phase II OptiTROP-Lung01 study." This study looks at the potential of combining sac-TMT and tagitanlimab as a first-line treatment option for patients with advanced NSCLC.
More on illi News
The remaining two studies, "Sacituzumab Tirumotecan (sac-TMT) in patients (pts) with previously treated locally advanced or metastatic (LA/M) non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: Preliminary results from a phase 2 study" and "Results from a phase I study of KL590586 in patients with advanced RET-mutant medullary thyroid cancer," will both be presented as poster presentations on May 31st and June 2nd respectively.
These studies demonstrate Kelun's commitment to developing innovative treatments for various types of cancer. The results presented at ASCO 2025 have the potential to significantly impact the lives of patients and improve their outcomes. The company looks forward to sharing their findings with the medical community at this prestigious event.
The abstracts for these studies will be published on ASCO's official website on May 22, 2025, local time. The selected studies for ASCO 2025 are focused on various types of cancer and aim to present promising treatment options for patients.
One of the studies, titled "Sacituzumab tirumotecan (sac-TMT) in patients with previously treated advanced EGFR-mutated non-small cell lung cancer (NSCLC): Results from the randomized OptiTROP-Lung03 study," will be presented as an oral presentation on June 1st. This study focuses on the use of sac-TMT as a potential treatment option for patients with advanced NSCLC.
More on illi News
- InventHelp Inventor Develops New Makeup Application Machine (CHK-1097)
- New Professional Association to Study Principles of Hospitality Applied to the Delivery of Healthcare
- Clinical Endpoints Successfully Met in Study for Groundbreaking 12-Lead ECG Synthesis Technology Allowing Software Application to FDA: HeartBeam, Inc
- DATA BREACH ALERT: Edelson Lechtzin LLP Is Investigating Claims On Behalf Of Medical Express Ambulance, Inc. Customers Whose Data May Have Been Compromised
- Boston Industrial Solutions, Inc. Unveils Natron® 504N UV LED Inks Designed for EPSON Printheads
Another study, titled "Tagitanlimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (R/M NPC): Results from a randomized, double-blind, phase 3 study," will also be presented as an oral presentation on May 31st. This study looks at the effectiveness of tagitanlimab in combination with other treatments for patients with recurrent or metastatic nasopharyngeal carcinoma.
The Phase II OptiTROP-Breast05 study will also be presented as a rapid oral presentation on May 30th. This study focuses on the use of sac-TMT as a first-line treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/m TNBC).
In addition to these presentations, there will also be a poster presentation on May 31st for the study titled "Sacituzumab tirumotecan (sac-TMT) in combination with tagitanlimab (anti-PD-L1) in first-line (1L) advanced non-small-cell lung cancer (NSCLC): Non-squamous cohort from the phase II OptiTROP-Lung01 study." This study looks at the potential of combining sac-TMT and tagitanlimab as a first-line treatment option for patients with advanced NSCLC.
More on illi News
- Kavelle Christie: Trump's First 100 Days Mark Alarming Breakdown in Healthcare, Public Health, and Freedoms
- Naperville: 100 Block Locust Court Structure Fire
- Naperville: Bulk Brush Collection to Help Residents With Spring Yard Clean-Ups
- Late-Breaking Research from SK Life Science Labs at AACR Annual Meeting Shows p300-Selective Degraders are Potent Growth Inhibitors in Models of Aggressive Prostate Cancers and Solid Tumors
- OpenSSL Technical Advisory Committee Elections Now Open – Cast Your Vote
The remaining two studies, "Sacituzumab Tirumotecan (sac-TMT) in patients (pts) with previously treated locally advanced or metastatic (LA/M) non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: Preliminary results from a phase 2 study" and "Results from a phase I study of KL590586 in patients with advanced RET-mutant medullary thyroid cancer," will both be presented as poster presentations on May 31st and June 2nd respectively.
These studies demonstrate Kelun's commitment to developing innovative treatments for various types of cancer. The results presented at ASCO 2025 have the potential to significantly impact the lives of patients and improve their outcomes. The company looks forward to sharing their findings with the medical community at this prestigious event.
Filed Under: Business
0 Comments
Latest on illi News
- Chicago: Mayor Johnson Announces $2 Million In New Round of Community Grant Recipients
- People & Stories/Gente y Cuentos Announces New Board Leadership & Corporate Partnership Initiative
- Concert Violinist Addison Teng Redefines Music Education for a New Generation
- How to Fast-Track Your Way to the Top with The Code
- Azitra, Inc. to Present ATR-04 Program Update at ASCO 2025
- Naperville Residents Invited to 'Chat with the Chief' on May 1
- Ultra High Net Worth Team Partners with Arkadios Capital, Establishing Boutique Firm KRM Investment Counsel
- Lyricalmar Set To Release Powerful New Ep "MARCHIVES" May 16
- Water Quality Association's 50th Anniversary Makes a Splash with Interactive Digital Artwork
- Charleston, SC - ACSEC offers Rain Barrels Through Annual Program
- Greek Government Issues Landmark Ministerial Order Addressing Citizenship of Greek-born adoptees
- Baltimore Author Crafts Space Opera Where Human Questions Outshine Galactic Scale
- Stout Surpasses 60,000 Acres and 3 Billion Plants Scanned
- OpsVeda Announces Launch of TariffSight, the World's First Comprehensive Platform to Address Tariff-Driven Challenges
- Crescent Grove Advisors Marks a Decade of Independence
- MAJOR New release of Krypto500 (ELF-HF) Sigint - COMINT software
- "The Eyes Have It" a Short Story by Philip K. Dick Now Available on Audiobook
- New Build-to-Suit VA Medical Office Facility Coming to Highland Heights, KY
- Oncolytics Biotech® to Showcase New Pancreatic Cancer Data at ASCO Highlighting Pelareorep's Tumor-Fighting Mechanism of Action
- Locus Robotics Surpasses 5 Billion Pick Milestone, Accelerating Global Adoption of Mobile Warehouse Automation USA - English USA - English